{"id":"histamine-dihydrochloride-and-il-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Histamine dihydrochloride acts as an immunomodulator that enhances immune cell function, while IL-2 (interleukin-2) is a cytokine that promotes T-cell proliferation and activation. Together, they work synergistically to boost the body's natural anti-tumor immune response by increasing lymphocyte activity and cytokine production.","oneSentence":"This combination therapy stimulates immune cells through histamine receptor signaling and IL-2-mediated T-cell activation to enhance anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:31:31.651Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"},{"name":"Renal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT05451784","phase":"PHASE1, PHASE2","title":"Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS","status":"RECRUITING","sponsor":"Fundacio Clinic Barcelona","startDate":"2022-07-20","conditions":"Metastatic Triple-Negative Breast Carcinoma","enrollment":20},{"nctId":"NCT05810792","phase":"PHASE2","title":"Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sahlgrenska University Hospital","startDate":"2024-04-01","conditions":"Pancreatic Cancer, Surgery, Metastasis","enrollment":50},{"nctId":"NCT05353101","phase":"PHASE1","title":"Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2020-07-01","conditions":"Vernal Keratoconjunctivitis, Cyclosporine 0.05% Eye Drops","enrollment":48},{"nctId":"NCT01770158","phase":"","title":"Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS)","status":"TERMINATED","sponsor":"University of Ulm","startDate":"2012-10","conditions":"Acute Myeloid Leukemia","enrollment":8},{"nctId":"NCT03040401","phase":"PHASE1, PHASE2","title":"A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)","status":"UNKNOWN","sponsor":"Vastra Gotaland Region","startDate":"2017-02-15","conditions":"Leukemia, Myelomonocytic, Chronic","enrollment":15},{"nctId":"NCT01347996","phase":"PHASE4","title":"Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Cytovia, Inc.","startDate":"2009-07","conditions":"Acute Myeloid Leukemia","enrollment":84},{"nctId":"NCT01324960","phase":"PHASE1, PHASE2","title":"Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes","status":"WITHDRAWN","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2011-03","conditions":"Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT00003991","phase":"PHASE3","title":"Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Maxim Pharmaceuticals","startDate":"1998-07","conditions":"Leukemia","enrollment":360},{"nctId":"NCT00005038","phase":"PHASE2","title":"Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer","status":"UNKNOWN","sponsor":"The Christie NHS Foundation Trust","startDate":"1999-06","conditions":"Kidney Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ceplene","Proleukin","IL-2","interleukin-2","histamine"],"phase":"marketed","status":"active","brandName":"histamine dihydrochloride and IL-2","genericName":"histamine dihydrochloride and IL-2","companyName":"Cytovia, Inc.","companyId":"cytovia-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy stimulates immune cells through histamine receptor signaling and IL-2-mediated T-cell activation to enhance anti-tumor immunity. Used for Metastatic melanoma, Renal cell carcinoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}